Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Given Average Rating of “Hold” by Analysts

Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) have been given an average rating of “Hold” by the five analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $22.75.

Several brokerages have recently commented on ADIL. Brookline Capital Markets downgraded shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Needham & Company LLC downgraded shares of Adial Pharmaceuticals to a “buy” rating in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Monday, April 20th.

Adial Pharmaceuticals Price Performance

Adial Pharmaceuticals stock opened at $2.98 on Monday. The company has a market capitalization of $6.38 million, a PE ratio of -0.37 and a beta of 1.46. The firm has a fifty day simple moving average of $1.86 and a two-hundred day simple moving average of $3.60. Adial Pharmaceuticals has a twelve month low of $1.31 and a twelve month high of $18.90.

Adial Pharmaceuticals (NASDAQ:ADIL) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.48) earnings per share for the quarter, topping the consensus estimate of ($2.73) by $1.25. As a group, equities analysts expect that Adial Pharmaceuticals will post -7.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adial Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ADIL. Armistice Capital LLC bought a new position in shares of Adial Pharmaceuticals during the fourth quarter valued at about $562,000. Citadel Advisors LLC bought a new position in shares of Adial Pharmaceuticals during the third quarter valued at about $51,000. Finally, Jane Street Group LLC raised its stake in shares of Adial Pharmaceuticals by 887.3% during the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after acquiring an additional 109,500 shares during the last quarter. 16.41% of the stock is owned by institutional investors.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.